Clinical Characteristics and Reasons for Differences in Duration From Symptom Onset to Release From Quarantine Among Patients With COVID-19 in Liaocheng, China

Suochen Tian, Zhenqin Chang, Yunxia Wang, Min Wu, Wenming Zhang, Guijie Zhou, Xiuli Zou, Hui Tian, Tingfang Xiao, Junmin Xing, Juan Chen, Jian Han, Kang Ning, Tiejun Wu, Suochen Tian, Zhenqin Chang, Yunxia Wang, Min Wu, Wenming Zhang, Guijie Zhou, Xiuli Zou, Hui Tian, Tingfang Xiao, Junmin Xing, Juan Chen, Jian Han, Kang Ning, Tiejun Wu

Abstract

Objective: This study aimed to identify additional characteristics and features of coronavirus disease (COVID-19) by assessing the clinical courses among COVID-19 patients in a region outside Hubei province. Methods: We analyzed retrospective data regarding general characteristics, epidemiologic history, underlying chronic diseases, clinical symptoms and complications, chest computed tomography findings, biochemical monitoring, disease severity, treatments, and outcomes among 37 adult patients with COVID-19. According to the duration from symptom onset to release from quarantine, the patients were divided into the ≤20 and >20-day groups, and the similarities and differences between them were compared. Results: Among the 37 patients, five had mild disease, 30 had moderate disease, one had severe disease, and one was critically ill. All of the patients were released from quarantine, and no mortality was observed. The average duration from symptom onset to release from quarantine was 20.2 ± 6.6 days. The average duration from symptom onset to hospitalization was 4.1 ± 3.7 days, and the patients were hospitalized for an average of 16.1 ± 6.2 days. The average age was 44.3 ± 1.67 years, and 78.4% of cases were caused by exposure to a patient with confirmed disease or the workplace of a patient with confirmed disease. The main symptoms were cough (67.6%), fever (62.2%), shortness of breath (32.4%), fatigue (24.3%), sore throat (21.6%), vomiting, and diarrhea (21.6%). White blood cell count was decreased in 27.0% of patients, and lymphocyte count was decreased in 62.2% of the patients, among whom 43.5% patients had counts of ≤0.6 × 109/L. On admission, 86.5% of patients showed pneumonia in chest CT scans, including some asymptomatic patients, while 68.8% of patients showed bilateral infiltration. In the >20-day group, the average age was 49.9 ± 1.38 years, and the average duration from symptom onset to hospitalization was 5.5 ± 3.9 days. Compared with the ≤20-day group, patients in the >20-day group were older and the duration was longer (P < 0.05). All of the seven asymptomatic patients belonged to the ≤20-day group. When the 37 patients were released from quarantine, the white blood cell count of 16.2% of the patients was <4.0 × 109/L, the lymphocyte count of 59.5% of the patients was <1.1 × 109/L, and the absolute counts of white blood cells and lymphocytes were 5.02 ± 1.34 × 109/L and 1.03 ± 0.34 × 109/L, respectively, compared with those recorded on admission (P > 0.05). Conclusion: The majority of COVID-19 cases in the study area were mild and moderate, with good clinical outcomes. There were some special characteristics in the clinical course. The reasons for differences in the duration from symptom onset to release from quarantine were complex. There was no significant change in the number of granulocytes at the time of release from quarantine compared to that at the time of admission.

Keywords: COVID-19 patients; clinical characteristic; epidemiologic characteristic; granulocyte count; quarantine.

Copyright © 2020 Tian, Chang, Wang, Wu, Zhang, Zhou, Zou, Tian, Xiao, Xing, Chen, Han, Ning and Wu.

References

    1. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. (2020) 382:1708–20. 10.1056/NEJMoa2002032
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. 10.1016/S0140-6736(20)30183-5
    1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. . Epidemiological and clinical characteristics of 99 cases of pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. 10.1016/S0140-6736(20)30211-7
    1. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. . Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. (2020). 10.1111/all.14238. [Epub ahead of print].
    1. Wu ZG, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. (2020) 323:1239–1242. 10.1001/jama.2020.2648
    1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. (2020) 323:1061–9. 10.1001/jama.2020.1585
    1. Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA. (2020) 323:1092–3. 10.1001/jama.2020.1623
    1. National Health Commission of the People's Republic of China, National Administration of Traditional Chinese Medicine The Protocol of Diagnosis and Treatment of Novel Coronavirus Pneumonia (5th Edition). Beijing: General office of National Health Commission; (2020).
    1. National Health Commission of the People's Republic of China, National Administration of Traditional Chinese Medicine The Protocol of Diagnosis and Treatment of Novel Coronavirus Pneumonia (6th edition). Beijing: General office of National Health Commission; (2020).
    1. National Health Commission of the People's Republic of China, National Administration of Traditional Chinese Medicine The Protocol of Diagnosis and Treatment of Novel Coronavirus Pneumonia (7th edition: ). Beijing: General office of National Health Commission; (2020).
    1. ARDS Definition Task Force. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. . Acute respiratory distress syndrome: the Berlin definition. JAMA. (2012) 307:2526–33. 10.1001/jama.2012.5669
    1. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. 2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis. J Med Virol. Mar. (2020) 92:577–583.
    1. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al. . Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. (2020) 395:e52. 10.1016/S0140-6736(20)30558-4
    1. Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, Iqbal M, et al. . Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. (2020) 24:2012–9. 10.26355/eurrev_202002_20379
    1. Nayman Alpat S, Usluer G, Ozgunes I, Doyuk Kartal E, Erben N. Clinical and Epidemiologic Characteristics of Hospitalized Patients with 2009 H1N1 Influenza Infection. Influenza Res Treat. (2012) 2012:603989. 10.1155/2012/603989
    1. MacIntyre CR, Chughtai AA, Barnes M, Ridda I, Seale H, Toms R, et al. . The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a (H1N1) pdm09. BMC Infect Dis. (2018) 18:637. 10.1186/s12879-018-3548-0
    1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. . Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. (2020) 382:1199–207. 10.1056/NEJMoa2001316
    1. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. (2020) 323:1406–7. 10.1001/jama.2020.2565
    1. Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res. (2020) 155:104743 10.1016/j.phrs.2020.104743
    1. Ling Chang-Quan. Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2). J Integr Med. (2020) 18:87–8. 10.1016/j.joim.2020.02.004
    1. Wen CC, Shyur LF, Jan JT, Liang PH, Kuo CJ, Arulselvan P, et al. . Traditional Chinese medicine herbal extracts of Cibotium barometz, Gentiana scabra, Dioscorea batatas, Cassia tora, and Taxillus chinensis inhibit SARS-CoV replication. J Tradit Complement Med. (2011) 1:41–50. 10.1016/S2225-4110(16)30055-4
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. 10.1016/S0140-6736(20)30566-3
    1. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. . Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. (2020). 10.1001/jamainternmed.2020.0994. [Epub ahead of print].

Source: PubMed

3
Subscribe